Disease relevance of Iproplatinum [Latin]

• Myelosuppression was the main toxicity and was greater with iproplatin [1].
• Phase II study of iproplatin in advanced ovarian carcinoma [2].
• PURPOSE: The Pediatric Oncology Group (POG) conducted a randomized phase II study to evaluate the activity of carboplatin and iproplatin in children with progressive or recurrent brain tumors [3].
• Twenty-five women with advanced breast cancer were treated in a phase II trial of iproplatin 275 mg/m2 administered intravenously every 4 weeks [4].
• Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung [5].

High impact information on Iproplatinum [Latin]

• Cisplatin and iproplatin induced an increase in the number of lysosomes in the light green cells [6].
• A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer [1].
• Incubation of iproplatin with ascorbic acid and cysteine, in vitro, indicates that iproplatin can be easily reduced to cis-dichloro-bis-isopropylamineplatinum(II) by reducing agents [7].
• The SCC-25/CP cell line is approximately 30-fold resistant to CDDP, approximately 10-fold resistant to carboplatin, and about 9-fold resistant to iproplatin [8].
• The pharmacokinetics of iproplatin, a quadrivalent second-generation platinum complex the dose-limiting toxicity of which is myelosuppression, was studied in patients with different degrees of renal function impairment [9].

Chemical compound and disease context of Iproplatinum [Latin]

• The spectrum and severity of toxicity of iproplatin were found to differ from those of cisplatin [10].
• Although this combination possesses therapeutic activity, given its toxicities, further evaluation of doxorubicin in combination with iproplatin is not recommended [11].
• To produce a given level of regrowth delay in lung cancer spheroids, carboplatin and iproplatin were required at concentrations approximately 10 times that of cis-DDP [12].
• Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma [13].
• The effect of cisplatin, carboplatin, oxoplatin, and iproplatin on delayed-type hypersensitivity in mice was studied [14].

Biological context of Iproplatinum [Latin]

• Similarly, at iproplatin doses of 75 mg/m2, 95 mg/m2, and 120 mg/m2, the lowest median platelet counts were 144 x 10(3)/mm3, 99 x 10(3)/mm3, and 31 x 10(3)/mm3, respectively [15].
• The range in IC50 values across the five lines was approximately 2.5-fold for cisplatin, carboplatin and iproplatin, 13-fold for tetraplatin and JM216, and 25-fold for JM221 [16].
• Efflux studies carried out to explore this possibility with cells in the whole blood showed that iproplatin was taken up into cells, but the efflux of protein-binding iproplatin metabolites did not occur [17].
• Our results, from the analyses of both GSH concentration as well as GSH per cell number, suggest a significantly higher interaction between GSH and iproplatin compared with the other platinum agents [18].
• Mutagenesis and cytotoxicity were studied in Escherichia coli by iproplatin and carboplatin, two analogs of cisplatin (CDDP) currently undergoing clinical trial [19].

Anatomical context of Iproplatinum [Latin]

• With iproplatin doses 75 mg/m2, 95 mg/m2, and 120 mg/m2, the lowest median granulocyte counts were 2.6 x 10(3)/mm3, 2.2 x 10(3)/mm3, and 1.8 x 10(3)/mm3, respectively [15].
• In the case of iproplatin and paraplatin rapid platinum clearance was noted from the glomeruli, blood vessels and renal medulla within 2 h of administration [20].
• Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial [21].
• A total of 48 patients with measurable advanced gastric adenocarcinoma (n = 16) or adenocarcinoma of the exocrine pancreas (n = 32) were prospectively treated with iproplatin at a starting dose of 270 mg/m2 intravenously over 2 hours [22].
• The effect of a second generation platinum chemotherapy agent, cis-dichloro-bis (isopropylamine) trans-dihydroxy platinum IV (iproplatin) on intracellular elements was investigated by analyzing subcellular compartments of drug-treated synchronous CHO cell populations [23].

Associations of Iproplatinum [Latin] with other chemical compounds

• Two analogues of CDDP, carbo- and iproplatin, effectively enhanced NK activity, but transplatin had no effect [24].
• We have also identified cis-dichloro-bis-isopropylamine platinum(II) (CIP) as a major metabolite of iproplatin [17].
• The clinical effectiveness of the other platinum compounds (iproplatin, oxaliplatin, and others) has not yet been fully tested as first-line chemotherapy [25].

Gene context of Iproplatinum [Latin]

• The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma [26].
• The results indicate that in patients receiving the drug, the reduction of iproplatin to CIP must take place intracellularly and that CIP or its protein-binding derivatives must efflux from the cells into the plasma [17].
• Urinary protein and enzyme excretion was measured in 33 patients with solid tumours receiving chemotherapy with the cis-platinum analogs carboplatin (JM8, CBDCA) and iproplatin (JM9, CHIP) [27].
• Levels of three enzymes, leucine aminopeptidase (LAP), N-acetyl-beta-D-glucosaminidase (NAG), and beta-glucuronidase (BGA) were measured in the urine of patients receiving hematologically toxic doses of iproplatin (a) with or (b) without pretreatment hydration [28].
• Iproplatin showed relatively marked binding to proteins of higher mol. wt. but no transfer with time to the low mol. wt. protein zone [29].

Analytical, diagnostic and therapeutic context of Iproplatinum [Latin]

• Cyclic fluctuations in nonprotein thiol levels were observed that correlated with a cyclic change in cellular sensitivity to the platinum-based chemotherapy drug iproplatin (CHIP) [30].
• In plasma and urine of patients receiving this drug, iproplatin- and platinum-containing metabolites of iproplatin were separated by reverse-phase gradient high performance liquid chromatography [7].
• Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center [31].
• Iproplatin was administered via a temporary dialysis catheter (n = 11) or a semi permanent Tenckhoff peritoneal dialysis catheter (n = 2) [32].
• Forty-eight patients with advanced breast cancer were treated in a disease-specific phase I trial of doxorubicin and iproplatin combination chemotherapy [11].

References